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Abstract
Purpose
A patient-derived xenograft (PDX) model is an in vivo animal model which provides biologi-
cal and genomic profiles similar to a primary tumor. The characterization of factors that influ-
ence the establishment of PDX is crucial. Furthermore, PDX models can provide a platform
for chemosensitivity tests to evaluate the effectiveness of a target agent before applying it in
clinical trials.
Methods
We implanted 83 cases of breast cancer into NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic mice, to
develop PDX models. Clinicopathological factors of primary tumors were reviewed to iden-
tify the factors affecting engraftment success rates. After the establishment of PDX models,
we performed olaparib and carboplatin chemosensitivity tests. We used PDX models from
triple-negative breast cancer (TNBC) with neoadjuvant chemotherapy and/or germline
BRCA1 mutations in chemosensitivity tests.
Results
The univariate analyses (p<0.05) showed factors which were significantly associated with
successful engraftment of PDX models include poor histologic grade, presence of BRCA
mutation, aggressive diseases, and death. Factors which were independently associated
with successful engraftment of PDX models on multivariate analyses include poor histologic
grade and aggressive diseases status. In chemosensitivity tests, a PDX model with the
BRCA1 L1780P mutation showed partial response to olaparib and complete response to
carboplatin.
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Conclusions
Successful engraftment of PDX models was significantly associated with aggressive dis-
eases. Patients who have aggressive diseases status, large tumors, and poor histologic
grade are ideal candidates for developing successful PDX models. Chemosensitivity tests
using the PDX models provide additional information about alternative treatment strategies
for residual TNBC after neoadjuvant chemotherapy.
Introduction
Drug development is facilitated by understanding of the interactions between tumors and
microenvironments. Preclinical models enhance knowledge of tumor biology and drug devel-
opment to elucidate drug resistant mechanisms of tumors. Appropriate selection of preclinical
models is pivotal to bridge the translational gap between drug development and clinical
application.
Triple negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER),
progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2). Compared
to hormone receptor-positive breast cancer, TNBC exhibits aggressive clinical characteristics
[1]. Cytotoxic chemotherapy is the only systemic treatment option to manage TNBC, because
of a lack of effective target therapy [2].
Pharmaceutical companies have invested in research and development (R&D) to find an
effective target therapy. However, many hurdles block the development of new drugs, includ-
ing the significant cost in terms of money and time. In 2000, the R&D cost per new drug,
including the pre-clinical and clinical cost was, on average US 802 million dollars [3]. The
mean duration of the clinical and approval phase, from investigational new drug application
filing to new drug application submission and approval, was 87.4 months [4]. Although new
agents have been discovered, the successful clinical trial process is difficult [5]. A new strategy
for successful clinical trial is necessary to overcome these challenges [6].
Drug sensitivity tests can be performed in in vitro models [7] whereby cancer cells are
directly exposed to various drug combinations in multiple concentrations. This kind of study
is considered a basic experiment before further evaluations of the drug can be tested in clinical
trials [8]. However, even well-designed artificial conditions for cancer cell lines do not directly
reflect patients’ micro-environments [9, 10].
Mouse models, or in vivo models, use patient-derived cancer cells to induce tumors in
mice. Animal models can simulate interaction between tumors and the microenvironment
[11, 12]. However, in vivo models which use cultured cancer cells of in vitro studies have the
same limitation because they also do not accurately reflect the characteristics of a patient’s pri-
mary tumor [13–15].
Patient-derived xenograft (PDX) models which use immune-compromised mice implanted
with fresh tumor tissue from patients with cancer have been introduced as new in vivo models
for cancer research [16, 17]. In general, tumors in PDX models have shown similar histopatho-
logical features as primary tumors [18]. Therefore, theoretically, PDX models can predict drug
response of primary tumors better than conventional in vivo or in vitro models [19–21].
Patient-derived xenograft models have been established for several cancer types [22–25]
and successful take rates of PDX models vary according to cancer type. Previous studies have
reported 10–50% success rates of PDX models in colon, pancreas, lung, prostate, and breast
cancer [26]. To enhance successful engraftment and maintenance of PDX models, it is crucial
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to characterize the factors influencing the establishment of PDX models, but little is known
about those factors.
The current study focused on the establishment of PDX models of breast cancer and identi-
fying the influencing factors for successful engraftment of the models. Furthermore, in vivo
chemosensitivity tests were performed in the PDX models with TNBC, with and without
highly aggressive diseases characteristics, and BRCAness.
Materials and methods
Patients and subtypes
A total of 82 patients with breast cancer were enrolled in this study. One patient who received
serial biopsies including a preoperative needle biopsy and surgical resection before (BR30) and
after (BR40) neoadjuvant chemotherapy was also included. Thus, a total of 83 malignant
tumors of breast were used to develop PDX models in the study. All patients underwent breast
surgery or biopsy at Severance Hospital, Seoul, Korea. Fresh tumor tissue was obtained during
surgery or biopsy. After removal, tumor tissue was immediately transferred to the animal labo-
ratory (Avison Biomedical Research Center, Seoul, Korea). Cubic tissue of 3mm3 in size was
minced and directly implanted into mice without delay. We attempted to establish PDX mod-
els from TNBC (n = 65), luminal A or B (n = 13), and HER2 positive (n = 5) breast cancer
patients. Among TNBC patients, 39 received neoadjuvant chemotherapy.
PDX models and establishment periods
Tumor tissue was implanted into the subcutaneous or mammary fat pad of 6 to 12-week-old
female NOG (NOD.Cg-Prkdcscid Il2rgtm1Sug) mice [27]. Tumor size was measured using
calipers once a week, and tumor volume was calculated as 0.5 × Length × Width2[28]. When
the tumor volume reached 1500 mm3-, the implanted tumor was harvested from the mice
under isoflurane anesthesia [26]. A portion of the tumor (~5mm3) was engrafted in a new gen-
eration of mice [29]. The remaining tumor was cut into pieces and stored in liquid nitrogen.
The tumor tissue was stored in a solution of 90% fetal bovine serum (FBS) and 10% dimethyl
sulfoxide (DMSO) for use in re-engraftment. Some of the tumor tissues were stored frozen for
generating sequencing data [30]. Primary tumor was implanted into the first generation of
mice, which was defined as F1 mice. The harvested tumor was serially implanted into second-
(F2) and third-generation (F3) of mice. When the PDX model had been engrafted into third
generation of mice, it was considered a successful PDX model [31].
Establishment periods from F1 to F3 (F1-F3) were measured. The establishment period was
divided into establishment periods from F1 to F2 (F1-F2) and F2 to F3 (F2-F3), and compared.
Establishment periods from F1 to F3 (F1-F3) was not exceeded 550 days.
Animal care
All animal experiments were performed in a facility accredited by AAALAC International
(#001071) in accordance with Guide for the Care and Use of Laboratory Animals 8th edition,
NRC (2010). The tumor implanted mice were housed in one cage (maximum five mice). Food
was exchanged once a week and water was supplied automatically from the automatic water
supply equipment. A facility staff of animal laboratory periodically checked the status of mice.
Mice monitoring was performed once a week. After tumor implantation, euthanasia was per-
formed when tumors reached 1500mm3 in volume or became ulcerated, tumors affected phys-
iological functions including gait, posture, ability to eat/drink/urinate/defecate, or when mice
lost more than 15% of their first body weight. Mice were euthanized by CO2 gas inhalation in
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accordance with the humane endpoints which included the above descriptions. And when the
mice reached endpoint criteria, we performed euthanasia by CO2 gas inhalation within 2 days.
In our study, there were no mice which died before meeting criteria for euthanasia. There are
well-trained facility staffs who can help to solve the problem in animal care at our institution.
They advised injection methods of drugs (carboplatin/olaparib).
Histopathological confirmation
When a tumor was engrafted to a new mouse, one piece of tumor tissue (~8mm3) was used to
construct FFPE (Formalin fixed paraffin embedded) blocks. Immunohistochemistry analysis
was performed to confirm the histopathological similarity including ER, PR, and HER2
between primary tumor and those in PDX models. Xylene and serial concentrations of ethanol
were used for deparaffinization and hydration of tumor sections. For antigen retrieval and
blocking endogenous peroxidases, a solution of 0.4% H2O2 and 10mM sodium citrate buffer
(pH6.0) was used. Sections were treated with a peroxidase-conjugated polymer solution (Dako
REAL EnVision Detection System, Peroxides/DAB+, antibodies of Rabbit/Mouse). Primary
antibodies used for in immunohistochemistry analysis included ERα (clone SP1, 1:100 dilu-
tion, LifeSpan BioSciences, Seattle, WA, USA); PR (clone 1E2, 1:100 dilution, ABCAM, Cam-
bridge, CB4 0FL, UK), HER2 (clone EP1045Y, 1:100 dilution, ABCAM, Cambridge, CB4 0FL,
UK) and Ki67 (clone EPR3610, 1:500 dilution, ABCAM, Cambridge, CB4 0FL, UK). A pathol-
ogist confirmed all stained slides.
Factors relating to success of PDX models
Clinicopathological factors relating to the successful engraftment of PDX models were ana-
lyzed. These factors included age, T-stage, nodal status, hormone receptor status, HER2 status,
Ki67 level, breast cancer subtype, histologic grade, treatment status, biopsy method (surgery or
needle biopsy), engraftment period, mouse type, TNM Classification of Malignant Tumours
(TNM) stage, existence/absence of BRCA mutation, and survival status of patient. Disease bur-
den was analyzed. Aggressive diseases were defined as progressive diseases during preoperative
or neoadjuvant chemotherapy, recurrent, and metastatic diseases.
Chemosensitivity tests using the PDX models
We performed chemosensitivity tests using three PDX models including a tumor from TNBC
with a novel germline pathogenic BRCA1 mutation, c.5339T->C; p.Leu1780Pro; rs80357474
(L1780P), which was introduced in our previous study [32], a tumor from TNBC with a germ-
line BRCA1 deleterious mutation, c.3277delG; p.Val1093SerfsTer16; rs113900085, and a
tumor from a TNBC without germline pathogenic BRCA mutation. PDX models were derived
from patients who had BRCA1 mutation (n = 2, L1780P and rs113900085) and the wild type of
BRCA1 (n = 1). Each model comprised nine mice, which were divided equally into three
groups (1 group = 3 mouse, vehicle [PBS], olaparib, and carboplatin.). A total of 27 mice were
used in the chemosensitivity tests.
Dosages of olarparib and carboplatin were 50 mg/kg and 25 mg/kg, respectively [33, 34].
Olaparib was administrated via intraperitoneal injection for 28 consecutive days. Carboplatin
was administrated via intraperitoneal injection once a week. Duration of the in vivo test was
not exceeded 2 months. Tumor volumes were measured using the below equation,
Volume = 0.5 × Length × Width2
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Sequencing analysis of the PDX model with L1780P
Whole genome sequencing (WGS) and whole exome sequencing (WES) of one PDX model
with L1780P mutation were performed in collaboration with the Theragen company (Seoul,
Korea). The depth of WGS was 30X in buffy coat, 60X in primary tumor, and 30X in F1, F2,
and F3, respectively. WES was only performed in the primary tumor, and the depth of WES
was 250X.
Using the TruSeq Nano DNA Sample Preparation Kit from Illumina (San Diego, CA),
DNA sequencing libraries of WGS were constructed, according to the manufacturer protocol.
Quality of the amplified libraries was confirmed by electrophoresis on Agilent Bioanalyzer
High Sensitivity DNA Kit (part # 5067–4626) (Agilent, CA). The libraries were sequenced
using Illumina HiSeq2500 and Cluster generation. Then, 2 × 100 cycle sequencing reads, sepa-
rated by paired-end turnaround, were performed on the instrument using HiSeq Rapid SBS
Kit v2 (FC-402-4021) and HiSeq Rapid PE Cluster Kit v2 (PE-402-4002; Illumina, CA).
In the WES, the quality and quantity of purified DNA were assessed by fluorometry (Qubit,
Invitrogen) and gel electrophoresis, and the sample was hybridized with RNA probes, SureSe-
lect XT Human All Exon V5 Capture library. The captured targets were then pulled down by
biotinylated probe/target hybrids using streptavidin-coated magnetic beads (Dynabeads My
One Streptavidine T1; Life Technologies Ltd.). The resulting purified libraries were applied to
an Illumina flow cell for cluster generation and sequenced using 100 bp paired-end reads on
an Illumina Hiseq2500 sequencer, following the manufacturer’s protocols.
The quality of reads in the WGS and WES were confirmed using fastQC (v.0.10.1) [35],
which also expounded the basic quality for sequence quality score, GC content, N content,
length of distribution, and duplication levels. After examining the read quality, the low-quality
bases below Q20 were trimmed using Cutadapt (v.1.8.1) [36].
In order to remove mouse reads in PDX samples, BBMap [37] was applied to the fastq files
based on hg19 and Ensembl Release 77 reference genome for human and mouse, respectively.
Only reads that were classified as human reads were then analyzed.
Statistics and ethics
The SPSS statistics program version 23 (International Business Machines Crop., Armonk, NY,
USA) was used for all analyses. Categorical variables were examined using chi-square test or
Fisher’s exact test. Continuous variables were examined using student T-test. Multivariate
analyses were examined using binary regression models. Multivariate analyses were adjusted
for significant factors in univariate analyses. All statistical analyses were two-sided and p-val-
ues of less than 0.05 were considered statistically significant.
All tumor tissue was obtained with the patient’s written consent and the informed written
consent was provided by the patients. All procedures were approved by the Institutional
Review Board of Yonsei University Health System (IRB No.4-2012-0705). All experiments
were approved by the Institutional Animal Care and Use Committee in Yonsei University
Hospital System (YUHS-IACUC) and animals were maintained in a facility accredited by
AAALAC International (#001071) in accordance with Guide for the Care and Use of Labora-
tory Animals 8th edition, NRC (2010).
Results
Of the 83 tumor samples, most tumor tissue (65 out of 83 samples) came from TNBC patients
(Fig 1A). Only one tumor sample was subcutaneously implanted into mice. 78 tumors were
implanted into mammary fat pads. Successful engraftments of PDX models were established
in 19 TNBC cases. All successful engraftments of PDX models were implanted into mammary
Chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models
PLOS ONE | https://doi.org/10.1371/journal.pone.0225082 December 10, 2019 5 / 16
fat pads. We attempted to establish PDX models from residual tumors more than primary
tumors (Fig 1B). The overall success rates of PDX models were higher in cases with primary
TNBCs than those in residual TNBCs (38.5% for primary TNBC vs. 23.1% for residual
TNBCs) (Fig 1B). We established a PDX model with a novel germline pathogenic mutation of
BRCA1, L1780P (Patent pending, reference number; DPB172272).
A total of 21 successful PDX models were derived from TNBC patients. Of those, two cases
were classified as developed lymphoma. Except for those two cases, 19 tumors from PDX mod-
els coincided with the histopathological characteristics of primary tumors (Fig 2A).
Fig 1. Proportions of successful engraftment of PDX models. (A) Proportion of breast cancer subtypes. (B)
Successful engraftment of PDX models were derived from TNBC patient with or without neoadjuvant chemotherapy.
https://doi.org/10.1371/journal.pone.0225082.g001
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Immunohistochemistry revealed Ki67 expression in the PDX models Fig 2B. ER, PR, and
HER2 tumor samples were positive controls. (Fig 2C)
The establishment periods of F1-F3 interval are shown in Fig 3A. The median establishment
period from F1 to F3 was 221 days (range 93–550 days). The PDX models of residual TNBC
with neoadjuvant chemotherapy (Neo TNBC) showed shorter establishment periods than pri-
mary TNBC (p = 0.02; Fig 3B). The F2-F3 interval was significantly shorter than the F1-F2
interval (p = 0.00002; Fig 3B). The shortest interval of establishment period was the F2-F3
interval of Neo TNBC models (median 62 days, range 41–158 days; Fig 3B).
In univariate analysis, T-stage, histologic grade, estrogen receptor status, and Ki67 levels
were statistically significant (p<0.05) (Table 1). Presence of BRCA mutation, aggressive dis-
eases status, or death were related to successful PDX models (p<0.05). Hormone and HER2
positive cases made up a small portion of total cases (n = 18, 21.7%), and the results were not
significant in hormone and HER2 positive cases. All successful PDX models were made from
TNBC and Neo TNBC cases.
In 65 TNBC cases, histologic grade, Ki67 level, presence of BRCA mutation, aggressive dis-
eases status, and death were statistically significant on univariate analysis (p<0.05; Table 2).
Fig 2. Histopathological characteristics of successful engraftment of PDX models and patients. (A) H&E staining
and immunohistochemistry of PDX models and primary tumor of patients. (B) Ki67 expression of PDX models. (C)
Positive control of ER, PR and HER2 in immunohistochemistry.
https://doi.org/10.1371/journal.pone.0225082.g002
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Fig 3. Successful engraftment of F1 to F3 in PDX models. (A) Establishment periods of all successful PDX models
(B) F1-F2 and F1-F3 intervals according to status of neoadjuvant chemotherapy.
https://doi.org/10.1371/journal.pone.0225082.g003
Table 1. Analysis of factors related to PDX models.
Factors PDX status
Failure (%) Success (%) p-value
Age (years) <60 43 (67.2%) 14 (73.7%) 0.592
�60 21 (32.8%) 5 (26.3%)
T stage -T1 34 (56.7%) 5 (26.3%) 0.038
T2 22 (36.7%) 10 (52.6%)
T3-T4 4 (6.7%) 4 (21.1%)
Nodal status Negative 40 (65.6%) 8 (47.1%) 0.165
Positive 21 (34.4%) 9 (52.9%)
Histologic grade I/II 33 (56.9%) 3 (15.8%) 0.002
III 25 (43.1%) 16 (84.2%)
ER Negative 51 (79.7%) 19 (100.0%) 0.032
Positive 13 (20.3%) 0 (0.0%)
PR Negative 55 (85.9%) 19 (100.0%) 0.083
Positive 9 (14.1%) 0 (0.0%)
HER2 Negative 56 (87.5%) 19 (100.0%) 0.105
Positive 8 (12.5%) 0 (0.0%)
Ki67 (%, n = 79) <39 (n = 41) 38 (62.3%) 3 (16.7%) 0.001
�39 (n = 38) 23 (37.7%) 15 (83.3%)
BRCA mutation Absent 61(96.9%) 15(78.9%) 0.005
Present 2(3.1%) 4(21.1%)
Survival status Live 62(96.9%) 15(78.9%) 0.008
Death 2(3.1%) 4(21.1%)
Aggressive diseases� Absent 54 (87.5%) 10 (63.2%) 0.004
Present 10 (12.5%) 9 (36.8%)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index
� Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease
https://doi.org/10.1371/journal.pone.0225082.t001
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Tumor size was not significant in TNBC cases (p>0.05). In TNBC cases with neoadjuvant
chemotherapy, histologic grade, presence of BRCA mutation, aggressive diseases status, and
death were statistically significant (p<0.05) (Table 3). Information of the chemotherapy regi-
mens is presented in S1 Table.
Multivariate analyses showed poor histologic grade and aggressive diseases status were
independently associated with the successful engraftment of PDX models (p<0.05; Table 4),
and presence of BRCA mutation and death event were marginally associated with successful
engraftment of PDX models (p = 0.05; Table 4).
In the chemosensitivity tests, there were no significant differences in the average tumor vol-
ume of the three treatment arms in PDX models with wild type BRCA1 and the deleterious
BRCA1 mutation. However, nearly complete remission in the carboplatin arm and partial
remission in the olaparib arm were attained in the PDX model with the novel L1780P BRCA1
mutation (Fig 4A–4E).
In WGS, c.5339T>C, L1780P in BRCA1 was continuously detected in buffy coat, primary
tumor, F1, F2, and F3 tumors. However, variant allele frequency (VAF) was increased in late
passage. (Normal = 0.53, F0 = 0.63, F1 = 0.9, F2 = 1.0, F3 = 1.0). There was no pathogenic
germline mutation in buffy coat, primary tumor and PDX models, other than in L1780P in
WGS. In TCGA data, there was no c.5339T>C, L1780P variant among in BRCA1 mutations.
[38] When we investigated the L1780P mutation in a Korean database reported in a previous
study, there was no L1780P mutation in the normal population. [32]
Discussion
We demonstrated that the successful establishment of PDX models from TNBC patients is
related to poor clinicopathologic factors including large tumor size, poor histologic grade, and
Table 2. Analysis of factors related to TNBC PDX models.
Factors PDX status
Failure (%) Success (%) p-value
Age(years) <60 29 (63.0%) 14 (73.7%) 0.410
�60 17 (37.0%) 5 (26.3%)
T stage -T1 24 (54.5%) 5 (26.3%) 0.070
T2 17 (38.6%) 10 (52.6%)
T3-T4 3 (6.8%) 4 (21.1%)
Nodal status Negative 28 (63.6%) 8 (47.1%) 0.238
Positive 16 (36.4%) 9 (52.9%)
Histologic grade I/II 19 (45.2%) 3 (15.8%) 0.027
III 23 (54.8%) 16 (84.2%)
Ki67 (%, n = 79) <39 (n = 41) 23 (52.3%) 3 (16.7%) 0.010
�39 (n = 38) 21 (47.7%) 15 (83.3%)
BRCA mutation Absent 43(93.5%) 14(73.7%) 0.027
Present 3(6.5%) 5(26.3%)
Survival status Live 44(95.7%) 15(78.9%) 0.034
Death 2(4.3%) 4(21.1%)
Aggressive diseases� Absent 37 (80.4%) 10 (52.6%) 0.023
Present 9 (19.6%) 9 (47.4%)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index
� Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease
https://doi.org/10.1371/journal.pone.0225082.t002
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aggressive diseases status at the time of tissue sampling. Aggressive diseases, including progres-
sive diseases during neoadjuvant chemotherapy, recurrent disease, and metastatic disease at
presentation, were associated with the establishment of successful PDX models on multivariate
analysis. A previous study reported that TNBC patients with progressive disease during neoad-
juvant chemotherapy had higher xenograft take rate than those with stable diseases or partial
response after neoadjuvant chemotherapy (6 of 7 patients, 85.7% vs. 5 of 17 patients, 29.4%)
[39]. These findings were similar to our findings. Therefore, tumor tissue from patients with
TNBC with aggressive features may be the best candidate for establishing PDX models.
Large tumor size and poor histologic grade were significantly related to stable take rates in
successful PDX models. A previous study reported that large tumor size and grade were associ-
ated with successful engraftment of PDX in bladder cancer [40]. Similar results have also been
reported in pancreatic cancer where large tumor size (�T3) was shown to be related to suc-
cessful engraftment of PDX [41]. These studies suggested that large tumor size and poor histo-
logic grade are predictors of successful engraftment of PDX, and this is concordant with our
results. The analysis of factors related to the successful engraftment of PDX is crucial because
considerable time and funds are consumed making successful PDX models. When developing
PDX models, the more suitable the patients enrolled are, the less time and funds are required
in order to achieve engraftment. The results of this study will be helpful to improve pre-clinical
research. Furthermore, genomic research and drug tests in successful PDX models are neces-
sary to improve the performance of PDX models.
In the current study, the mean F1-F2 interval was longer than the mean F2-F3 interval. In
concordance with our results, a previous publication also demonstrated that the F1-F2 interval
was longer than the F2-F3 interval in successful breast cancer PDX models [39].
In this study, Neo TNBC PDX models had shorter establishment period intervals than
TNBC PDX models. These results suggested that shorter establishment period may be due to
Table 3. Analysis of factors related to TNBC PDX models with neoadjuvant chemotherapy.
Factors PDX status
Failure (%) Success (%) p-value
Age(years) <60 22 (73.3%) 8 (88.9%) 0.331
�60 8 (26.7%) 1 (11.1%)
T stage -T1 13 (44.8%) 2 (22.2%) 0.066
T2 13 (44.8%) 3 (33.3%)
T3-T4 3 (10.3%) 4 (44.4%)
Nodal status Negative 16 (55.2%) 2 (25.0%) 0.131
Positive 13 (44.8%) 6 (75.0%)
Histologic grade I/II 16 (59.3%) 1 (11.1%) 0.012
III 11 (40.7%) 8 (88.9%)
Ki67 (%, n = 79) <39 (n = 41) 17 (58.6%) 2 (22.2%) 0.056
�39 (n = 38) 12 (41.4%) 7 (77.8%)
BRCA mutation Absent 28(93.3%) 6(66.7%) 0.036
Present 2(6.7%) 3(33.3%)
Survival status Live 28(93.3%) 6(66.7%) 0.036
Death 2(6.7%) 3(33.3%)
Aggressive diseases� Absent 23 (76.7%) 2 (22.2%) 0.003
Present 7 (23.3%) 7(77.8%)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index
� Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease
https://doi.org/10.1371/journal.pone.0225082.t003
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the aggressive nature of residual tumors after neoadjuvant chemotherapy, compared to pri-
mary tumors [42]. Aggressiveness of tumors has been shown to affect the successful establish-
ment of PDX models and the rapid formation of tumor and tumor growth in the immune-
deficient mouse [43, 44]. It was concordant with our study. Thus, in terms of establishment
periods for establishing PDX models, residual TNBC after neoadjuvant chemotherapy may be
more suitable than primary tumor of TNBC.
Chemosensitivity tests using PDX models were introduced by previous studies [45–47].
However, only a few studies reported chemosensitivity tests using PDX models from residual
breast cancer after chemotherapy [48]. It has been suggested that BRCA mutations or BRCA-
ness are potential targets of PARP inhibitors and platinum agents [33, 49]. Thus, we performed
in vivo chemosensitivity tests of PARP inhibitor, olaparib and platinum agent, carboplatin, for
PDX models with residual TNBC with/without BRCA1 mutation. A potential benefit from ola-
parib and carboplatin was evident in the PDX model with the L1780P mutation, but not in the
other models. The establishment periods of PDX models remains a major challenge to apply-
ing them as in vivo chemosensitivity tests or the baseline study of N-of-1 trials. To overcome
this hurdle, appropriate selection criteria for enrollment of patients for the PDX models should
be considered. In this study, the median establishment period was 8 months. A limitation of
this study is that chemosensitivity tests of the PDX models with L1780P mutation were per-
formed in a single PDX model of one patient. Because the current study was conducted as an
initial step of proof-of-concept study of N-of-1 trial, the results provide additional information
about the potential application of chemosensitivity tests using PDX models. More chemosensi-
tivity tests of PDX models for a larger number of L1780P mutation cases may strengthen the
implications of further investigations of BRCA1 L1780P mutation olaparib and carboplatin
drug-sensitivity.
In the current study, histopathological characteristics of tumors in successful PDX models
were concordant with primary tumors. Interestingly, the sequencing analyses for the PDX
model with L1780P mutation showed the VAF of the mutation was different among passages.
This suggests that genetic alteration may occur throughout the passages. However, full geno-
mic analyses were not performed in either primary tumors or successful PDX models—which
was a limitation of this study. One of the advantages of PDX models is their ability to reflect
patients’ genomic and clinicopathologic characteristics. Therefore, sequencing data from
patients and PDX models is essential to examine the similarity of the genomic landscape
between the two [48, 50, 51].
Table 4. Multivariate analysis of factors relating to successful engraftment of PDX models.
Factors p-value OR 95% C.I.
All cases
(n = 83)
Histologic grade (I/II vs. III) 0.004 7.040 1.847–26.836
BRCA mutation (absent vs. present) 0.012 7.262 1.549–34.034
Survival status (live vs. Death) 0.021 8.247 1.382–49.444
Aggressive diseases (absent vs. present) 0.006 4.860 1.577–14.974
TNBC cases
(n = 65)
Histologic grade (I/II vs. III) 0.034 4.406 1.114–17.420
BRCA mutation (absent vs. present) 0.039 5.119 1.083–24.196
Survival status (live vs. Death) 0.053 5.867 0.974–35.339
Aggressive diseases (absent vs. present) 0.027 3.700 1.162–11.783
Neo TNBC cases
(n = 39)
Histologic grade (I/II vs. III) 0.030 11.636 1.269–106.719
BRCA mutation (absent vs. present) 0.056 7.000 0.952–51.448
Survival status (live vs. Death) 0.056 7.000 0.952-51-448
Aggressive diseases (absent vs. present) 0.007 11.500 1.930–68.518
https://doi.org/10.1371/journal.pone.0225082.t004
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Fig 4. Scheme and results of chemosensitivity tests using PDX models. (A) PDX models were derived from patients
who had BRCA1 mutation (n = 2) or wild-type BRCA1 (n = 1). Each model comprise nine mice, which were divided
into three groups (1 group = 3 mouse, two single treatment groups and one vehicle group). (B-E) When implanted
tumor reached an average size of 200–250 mm3 (Volume = 0.5×Length×Width^2), the chemosensitivity test was
performed. Olaparib (50mg/kg, once a daily) and carboplatin (25mg/kg, once a weekly) were administered by an intra-
peritoneal (i.p.) route. Phosphate buffered saline was used to as a vehicle.
https://doi.org/10.1371/journal.pone.0225082.g004
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PDX models often utilize immune deficient mouse to avoid rejection of the human tumor
graft by the mouse immune system. For this reason, PDX models using immune deficient
mouse cannot reflect crosstalk of the immune system and human tumors. A previous study
introduced a PDX model using humanized mice that was developed by injection of human
hematopoietic cells into the mice to overcome this limitation of PDX models using immune
deficient mice. [52, 53]
In further studies, it will be necessary to perform genomic sequencing and analysis of
sequencing data in all successful PDX models. Additional experiments are necessary for the
two suspected lymphoma to evaluate the mechanism of formation of lymphoma in PDX mod-
els [54].
Conclusions
The current study showed the feasibility of establishing PDX models using residual TNBC
after neoadjuvant chemotherapy. Patients who have aggressive diseases status, large tumors,
and poor histologic grade are ideal candidates for developing successful PDX models. This
study also showed the potential usefulness of in vivo chemosensitivity tests for tumors with tar-
getable biomarkers, particularly tumors with a novel pathologic mutation, L1780P. Further
genomic analyses of the PDX models may shed light on tumor progression and drug resistant
mechanisms in TNBC.
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